U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial

Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S.

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

US stock futures lower, MongoDB shares down 13.4% in pre-market trading after earnings beat estimate

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the C

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, o

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperf

Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% fr

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Con

Enrolled four patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.25 per share which beat the analy

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.14 per share which beat the analy

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the C

Zevra investors who relied on public statements about arimoclomol's approval status faced losses aft

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and pr

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Re

Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy a

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst

BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the pr

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease t

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

Under European regulatory procedures, the Company plans to request a re-examination of the CHMP opin

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and rais

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises

BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the p

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy a

Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overwe

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed pa

Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings pa